PT3024484T - Composições de anticorpo estabilizadas - Google Patents
Composições de anticorpo estabilizadasInfo
- Publication number
- PT3024484T PT3024484T PT14742509T PT14742509T PT3024484T PT 3024484 T PT3024484 T PT 3024484T PT 14742509 T PT14742509 T PT 14742509T PT 14742509 T PT14742509 T PT 14742509T PT 3024484 T PT3024484 T PT 3024484T
- Authority
- PT
- Portugal
- Prior art keywords
- antibody compositions
- stabilized antibody
- stabilized
- compositions
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13177699 | 2013-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3024484T true PT3024484T (pt) | 2018-10-24 |
Family
ID=48803483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT14742509T PT3024484T (pt) | 2013-07-23 | 2014-07-23 | Composições de anticorpo estabilizadas |
Country Status (15)
Country | Link |
---|---|
US (3) | US10273298B2 (pt) |
EP (1) | EP3024484B1 (pt) |
JP (1) | JP6503349B2 (pt) |
KR (1) | KR102272568B1 (pt) |
CN (2) | CN114028560A (pt) |
AU (1) | AU2014295052B2 (pt) |
BR (1) | BR112016001522B1 (pt) |
CA (1) | CA2918419C (pt) |
DK (1) | DK3024484T3 (pt) |
ES (1) | ES2687094T3 (pt) |
HK (1) | HK1224218A1 (pt) |
MX (1) | MX370207B (pt) |
PL (1) | PL3024484T3 (pt) |
PT (1) | PT3024484T (pt) |
WO (1) | WO2015011199A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011113855A2 (en) | 2010-03-17 | 2011-09-22 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
DK3192501T3 (da) | 2011-05-25 | 2020-08-03 | Novaliq Gmbh | Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner |
US9757460B2 (en) | 2012-01-23 | 2017-09-12 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
CA2883003C (en) | 2012-09-12 | 2021-11-16 | Novaliq Gmbh | Semifluorinated alkane compositions |
CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
EP2893939A1 (en) * | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
AR103726A1 (es) * | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
CN113662929A (zh) | 2015-09-30 | 2021-11-19 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
DK3355990T3 (da) | 2015-09-30 | 2019-09-16 | Novaliq Gmbh | Semifluorinerede forbindelser og disses sammensætninger |
US10507132B2 (en) * | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
CN116172987A (zh) | 2016-09-22 | 2023-05-30 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
ES2965677T3 (es) | 2016-09-23 | 2024-04-16 | Novaliq Gmbh | Composiciones oftálmicas que comprenden ciclosporina |
BR112019021917A8 (pt) | 2017-04-21 | 2023-03-21 | Novaliq Gmbh | Composições de iodo |
EP3618871A4 (en) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CN110650734A (zh) | 2017-05-12 | 2020-01-03 | 诺瓦利克有限责任公司 | 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物 |
CA3076776A1 (en) | 2017-09-27 | 2019-04-04 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
CA3091308A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
CA3111870C (en) | 2018-09-27 | 2022-04-12 | Novaliq Gmbh | Topical sunscreen formulation |
JP7360452B2 (ja) | 2018-09-27 | 2023-10-12 | ダーマリック セラピューティクス, インコーポレーテッド | 脂質バリアの修復 |
WO2020074697A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
CN113710228A (zh) * | 2019-02-13 | 2021-11-26 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的组合物和方法 |
KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
JP2023503287A (ja) | 2019-11-27 | 2023-01-27 | ノバリック ゲーエムベーハー | 非水性溶媒で懸濁されたタンパク質粒子を含む懸濁製剤 |
AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
US4452818A (en) | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
AU8192987A (en) * | 1986-12-01 | 1988-06-16 | Northwestern University | Human ldh-c4 cdna sequences encoding antigenic regions |
JPS6452722A (en) | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
IN184589B (pt) | 1996-10-16 | 2000-09-09 | Alza Corp | |
DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
DK0983037T3 (da) | 1998-02-09 | 2003-09-01 | Macrochem Corp | Fungicid neglelak |
DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
DE69912441T2 (de) | 1998-08-19 | 2004-08-19 | Skyepharma Canada Inc., Verdun | Injizierbare wässerige propofoldispersionen |
US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
EP1152749B1 (en) | 1999-02-08 | 2006-04-12 | ALZA Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
WO2000054588A1 (en) | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
US20030027833A1 (en) | 2001-05-07 | 2003-02-06 | Cleary Gary W. | Compositions and delivery systems for administration of a local anesthetic agent |
RU2302857C2 (ru) | 2001-09-04 | 2007-07-20 | Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель | Способ и пластырь для профилактики и/или лечения дисфункции и/или нарушения роста ногтей |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
CA2776692C (en) | 2003-08-25 | 2014-12-30 | Foamix Ltd. | Penetrating pharmaceutical foam |
US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
AU2004293027A1 (en) | 2003-11-19 | 2005-06-09 | Barnes-Jewish Hospital | Enhanced drug delivery |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
EP1740189B1 (en) | 2004-04-19 | 2012-06-13 | Centre National De La Recherche Scientifique -Cnrs- | Lung surfactant supplements |
WO2005123035A1 (en) | 2004-06-08 | 2005-12-29 | Ocularis Pharma, Inc. | Hydrophobic ophthalmic compositions and methods of use |
AU2005262392A1 (en) | 2004-07-01 | 2006-01-19 | Johnson & Johnson Vision Care, Inc. | Compositions and methods for treating eye disorders and conditions |
US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
GB0511499D0 (en) | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
WO2007052288A2 (en) | 2005-08-05 | 2007-05-10 | Bharat Serums & Vaccines Ltd. | Intravenous propofol emulsion compositions having preservative efficacy |
DE102005055811A1 (de) | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
WO2007149334A2 (en) | 2006-06-16 | 2007-12-27 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
CA2664879C (en) | 2006-09-29 | 2015-03-24 | Surmodics, Inc. | Biodegradable ocular implants and methods for treating ocular conditions |
WO2008070490A2 (en) | 2006-11-28 | 2008-06-12 | Wisconsin Alumni Research Foundation | Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics |
DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
DK2110126T3 (da) * | 2008-04-18 | 2012-02-27 | Novaliq Gmbh | Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område |
US20100000899A1 (en) * | 2008-07-07 | 2010-01-07 | Panasonic Corporation | Medication blister pack with embedded user interface |
CA2743824A1 (en) | 2008-11-26 | 2010-06-03 | Surmodics, Inc. | Implantable ocular drug delivery device and methods |
US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
US9012503B2 (en) | 2009-06-25 | 2015-04-21 | Lion Corporation | Ophthalmic composition |
JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
PL2387391T3 (pl) | 2009-07-24 | 2017-09-29 | Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Sposób otrzymywania ciekłej kompozycji stosowalnej w postaci piany na skórę oraz kompozycja do aplikowania miejscowego |
EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
EP2335735A1 (en) * | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
ES2659079T3 (es) | 2010-03-09 | 2018-03-13 | Janssen Biotech, Inc. | Formulaciones no acuosas en suspensión de viscosidad reducida a concentración elevada |
US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
WO2011113855A2 (en) | 2010-03-17 | 2011-09-22 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
DE102010022567A1 (de) | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
ES2711760T3 (es) | 2011-01-04 | 2019-05-07 | Novaliq Gmbh | Emulsiones de aceite/agua que comprenden alcanos semifluorados |
WO2012142670A1 (en) * | 2011-04-20 | 2012-10-26 | The University Of Queensland | Nuclear magnetic resonance agent |
CA2834862C (en) | 2011-05-25 | 2019-12-17 | Novaliq Gmbh | Pharmaceutical composition for administration to nails |
DK3192501T3 (da) | 2011-05-25 | 2020-08-03 | Novaliq Gmbh | Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner |
US9757460B2 (en) | 2012-01-23 | 2017-09-12 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
NZ725654A (en) | 2012-05-18 | 2018-04-27 | Genentech Inc | High-concentration monoclonal antibody formulations |
CA2883003C (en) | 2012-09-12 | 2021-11-16 | Novaliq Gmbh | Semifluorinated alkane compositions |
CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
JP2016502850A (ja) | 2012-12-18 | 2016-02-01 | ノバルティス アーゲー | ヒアルロナンに結合するペプチドタグを使用する組成物及び方法 |
EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
EP2944324A1 (de) | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
CN113662929A (zh) | 2015-09-30 | 2021-11-19 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
DK3355990T3 (da) | 2015-09-30 | 2019-09-16 | Novaliq Gmbh | Semifluorinerede forbindelser og disses sammensætninger |
KR102354198B1 (ko) | 2015-11-18 | 2022-01-20 | 에스아이오2 메디컬 프로덕츠, 인크. | Vegf-길항제의 액체 제제를 포함하는 사전-충전된 제약 패키지 |
JP2019501200A (ja) | 2016-01-08 | 2019-01-17 | クリアサイド バイオメディカル,インコーポレイテッド | 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス |
CN116172987A (zh) | 2016-09-22 | 2023-05-30 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
ES2965677T3 (es) | 2016-09-23 | 2024-04-16 | Novaliq Gmbh | Composiciones oftálmicas que comprenden ciclosporina |
EP3518921B1 (en) | 2016-09-28 | 2021-08-11 | Novaliq GmbH | Compositions comprising a cannabinoid receptor binding ligand |
CN116327963A (zh) | 2016-11-21 | 2023-06-27 | 济世-伊沃泰克生物制品有限公司 | 一种眼科制剂及其用途 |
MX2019007586A (es) | 2016-12-22 | 2019-12-11 | Novaliq Gmbh | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. |
ES2819005T3 (es) | 2016-12-23 | 2021-04-14 | Novaliq Gmbh | Composición oftálmica para el tratamiento de la enfermedad del ojo seco |
CN113710228A (zh) | 2019-02-13 | 2021-11-26 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的组合物和方法 |
JP2023503287A (ja) | 2019-11-27 | 2023-01-27 | ノバリック ゲーエムベーハー | 非水性溶媒で懸濁されたタンパク質粒子を含む懸濁製剤 |
-
2014
- 2014-07-23 US US14/907,254 patent/US10273298B2/en active Active
- 2014-07-23 AU AU2014295052A patent/AU2014295052B2/en active Active
- 2014-07-23 EP EP14742509.4A patent/EP3024484B1/en active Active
- 2014-07-23 PL PL14742509T patent/PL3024484T3/pl unknown
- 2014-07-23 BR BR112016001522-3A patent/BR112016001522B1/pt active IP Right Grant
- 2014-07-23 PT PT14742509T patent/PT3024484T/pt unknown
- 2014-07-23 CN CN202111078105.5A patent/CN114028560A/zh active Pending
- 2014-07-23 MX MX2016001018A patent/MX370207B/es active IP Right Grant
- 2014-07-23 JP JP2016528526A patent/JP6503349B2/ja active Active
- 2014-07-23 WO PCT/EP2014/065840 patent/WO2015011199A1/en active Application Filing
- 2014-07-23 CN CN201480040002.1A patent/CN105555311B/zh active Active
- 2014-07-23 KR KR1020167001802A patent/KR102272568B1/ko active IP Right Grant
- 2014-07-23 ES ES14742509.4T patent/ES2687094T3/es active Active
- 2014-07-23 DK DK14742509.4T patent/DK3024484T3/en active
- 2014-07-23 CA CA2918419A patent/CA2918419C/en active Active
-
2016
- 2016-11-03 HK HK16112636.7A patent/HK1224218A1/zh unknown
-
2019
- 2019-03-06 US US16/294,506 patent/US20190256591A1/en not_active Abandoned
-
2021
- 2021-05-14 US US17/320,693 patent/US11987623B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10273298B2 (en) | 2019-04-30 |
EP3024484B1 (en) | 2018-06-20 |
HK1224218A1 (zh) | 2017-08-18 |
CN105555311A (zh) | 2016-05-04 |
US20210340248A1 (en) | 2021-11-04 |
US20160159902A1 (en) | 2016-06-09 |
AU2014295052B2 (en) | 2018-08-30 |
DK3024484T3 (en) | 2018-10-08 |
CN114028560A (zh) | 2022-02-11 |
WO2015011199A1 (en) | 2015-01-29 |
US20190256591A1 (en) | 2019-08-22 |
KR102272568B1 (ko) | 2021-07-05 |
JP6503349B2 (ja) | 2019-04-17 |
EP3024484A1 (en) | 2016-06-01 |
ES2687094T3 (es) | 2018-10-23 |
US11987623B2 (en) | 2024-05-21 |
PL3024484T3 (pl) | 2018-11-30 |
MX2016001018A (es) | 2016-09-06 |
CN105555311B (zh) | 2021-10-08 |
KR20160034307A (ko) | 2016-03-29 |
AU2014295052A1 (en) | 2016-02-11 |
MX370207B (es) | 2019-12-05 |
CA2918419C (en) | 2022-05-03 |
CA2918419A1 (en) | 2015-01-29 |
BR112016001522B1 (pt) | 2019-10-01 |
JP2016525139A (ja) | 2016-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1224218A1 (zh) | 穩定的抗體組合物 | |
ZA202005525B (en) | Antibody formulations | |
IL244712B (en) | Anti- pdl1 antibody compositions | |
SG11201602596UA (en) | Stabilized efinaconazole compositions | |
GB201304662D0 (en) | Compositions | |
GB201319525D0 (en) | Composition | |
EP2889350A4 (en) | ADHESIVE COMPOSITION | |
GB201313615D0 (en) | Compositions | |
EP3006525A4 (en) | ASPHALT-URETHANE COMPOSITION | |
GB201318489D0 (en) | Composition | |
GB201317388D0 (en) | Composition | |
GB201300706D0 (en) | Antibody | |
GB201306984D0 (en) | Composition | |
EP3066178A4 (en) | GREASE COMPOSITION | |
GB201320303D0 (en) | Composition | |
GB201317196D0 (en) | Composition | |
GB201307622D0 (en) | Composition | |
GB201308502D0 (en) | Composition | |
GB201301774D0 (en) | Composition | |
GB201320962D0 (en) | Compositions | |
GB201318394D0 (en) | Composition | |
GB201320959D0 (en) | Compositions | |
GB201305622D0 (en) | Composition | |
GB201312224D0 (en) | Compositions | |
GB201304927D0 (en) | Compositions |